Global Animal Testing Reform 2025

The State of Animal Testing in 2025

Approximately 110-115 million animals are used in scientific research globally each year, with mice and rats constituting over 90% of that total. The global trend is toward reduction and replacement, driven by both ethical concerns and scientific evidence that animal models often fail to predict human responses accurately. Key policy developments and technological advances are accelerating this transition.

Major Policy Developments

Jurisdiction	Development	Year
USA	FDA Modernization Act 2.0 — removes requirement for animal testing for new drugs; allows alternative methods	2022
USA	EPA commitment to eliminate mammalian studies for pesticides	2019/ongoing
European Union	Resolution calling for phase-out of animal testing in research	2021
EU	Safety of cosmetics: animal testing ban complete for products and ingredients	2013/2023
UK	NC3Rs funds alternatives research; 3Rs embedded in regulatory framework	Ongoing

FDA Modernization Act 2.0: This US legislation is transformative — for the first time, it removes the legal requirement for animal studies to demonstrate drug safety, allowing FDA to accept data from cell-based assays, organ chips, computer models, and other human-relevant methods. This represents the most significant US regulatory shift in decades.

New Animal-Free Technologies

Organs-on-Chips

Microfluidic devices containing human cells that mimic the function of organs (liver-on-chip, lung-on-chip, gut-on-chip) can be linked to model drug responses in the human body with greater accuracy than many animal models. Companies including Emulate Bio have received FDA recognition for their organ chip platforms.

Organoids

Three-dimensional cell cultures that self-organize to resemble organs — including brain organoids, intestinal organoids, and tumor organoids — enable disease modeling and drug testing in human tissue without animals.

AI-Powered Prediction

Machine learning models trained on vast chemical and toxicological datasets can predict drug safety and efficacy with growing accuracy, reducing the need for in vitro and in vivo testing in screening phases.

Scientific Advantage: Beyond welfare benefits, alternative methods often outperform animal models in predicting human responses. Approximately 90% of drugs that pass animal testing fail in human clinical trials — partly due to species differences. Human-relevant alternative methods may actually improve drug development success rates.

Remaining Challenges

Regulatory validation: new methods need international validation and acceptance before replacing required animal studies
Complex systems: whole-body systemic effects (immunotoxicology, neurological effects) remain difficult to model without animals
Funding gaps: alternative methods research is underfunded relative to potential impact
Basic research: the 3Rs have had less impact on fundamental research than on testing applications